drugset / Trial / NCT06423352

A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension

NCT06423352

Phase 1/2 Completed 36 enrolled Alnylam Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics (PD) and pharmacokinetics (PK) of zilebesiran in Japanese patients with mild to moderate hypertension.

Timeline

Start
2024-06-05
Primary completion
2025-07-17
Completion
2025-07-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Zilebesiran Unknown Subcutaneous

Indications